Q2 2022

Filed Aug 15, 2022 · 10-Q · 46 days after period end · 0001654954-22-011398

Q2 2022 · 10-Q

Revenue—

Net Income

-$3.59M

N/M vs Q2 2021

EPS, diluted—

Operating Income-$3,571,693N/M

Operating Cash Flowderived-$3,334,982N/M

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	—	—	—	$0.00
Net Income	-$3.59M	-$3.20M	-$2.89M	-$2.33M
EPS Diluted	—	-$0.08	-$0.20	-$0.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR